Estradiol-delivering vaginal rings for hormone replacement therapy

被引:25
作者
Nash, HA
Alvarez-Sanchez, F
Mishell, DR
Fraser, IS
Maruo, T
Harmon, TM
机构
[1] Populat Council, New York, NY 10021 USA
[2] Univ So Calif, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA
[3] PROFAMILIA, Santo Domingo, Dominican Rep
[4] Univ Sydney, Dept Obstet & Gynecol, Sydney, NSW 2006, Australia
[5] Kobe Univ, Sch Med, Sydney Ctr Reprod Hlth Res, Kobe, Hyogo, Japan
[6] Kobe Univ, Sch Med, Dept Obstet & Gynecol, Kobe, Hyogo, Japan
关键词
estradiol; estrone; estrone sulfate; hormone replacement; vaginal rings;
D O I
10.1016/S0002-9378(99)70383-2
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVES: This study was undertaken to determine the relief of climacteric symptoms by vaginal rings delivering estradiol and to monitor estrogen levels. STUDY DESIGN: Rings releasing in vitro either 60 or 140 mu g/d estradiol were used by 35 women who had undergone hysterectomy for each dose level. Hot flash and night sweat incidences, vaginal conditions and complaints were recorded at clinic visits pretreatment and at 1 week, 2 weeks, 1 month, and monthly thereafter through 6 months. Serum samples were assayed for estradiol, estrone, and estrone sulfate. RESULTS: Hot flash incidence was reduced by about 80% with either ring. Vaginal conditions and mood were improved. Fourteen of 70 women discontinued ring use during the trial, 5 because of ring expulsions. Mean (+/-SD) estradiol levels were 123 +/- 48 and 307 +/- 93 pmol/L for the low and high dosage levels, respectively. Mean estrone levels exceeded estradiol levels by 1.7-fold far the higher dosage ring and 2.6-fold for the lower dosage ring. Increases in estrone sulfate concentrations were many times greater than those of estradiol or estrone. CONCLUSIONS: Vaginal rings are an acceptable method of delivery for periods of greater than or equal to 6 months of doses of estradiol that reduce vasomotor symptoms and improve vaginal conditions. There was little difference in these responses between the 2 dosage levels.
引用
收藏
页码:1400 / 1406
页数:7
相关论文
共 20 条
[1]   DIFFERENTIAL LIPEMIC AND HORMONAL RESPONSES TO ORAL AND PARENTERAL 17-BETA-ESTRADIOL IN POST-MENOPAUSAL WOMEN [J].
BASDEVANT, A ;
DELIGNIERES, B ;
GUYGRAND, B .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1983, 147 (01) :77-81
[2]   BIOLOGICAL EFFECTS OF ESTRADIOL-17-BETA-IN POSTMENOPAUSAL WOMEN - ORAL VERSUS PERCUTANEOUS ADMINISTRATION [J].
DELIGNIERES, B ;
BASDEVANT, A ;
THOMAS, G ;
THALABARD, JC ;
MERCIERBODARD, C ;
CONARD, J ;
GUYENE, TT ;
MAIRON, N ;
CORVOL, P ;
GUYGRAND, B ;
MAUVAISJARVIS, P ;
SITRUKWARE, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 62 (03) :536-541
[3]  
GORDON SF, 1995, INT J FERTIL MENOP S, V40, P126
[4]  
HAAS S, 1988, OBSTET GYNECOL, V71, P671
[5]  
HENDRICKSON L, 1994, AM J OBSTET GYNECOL, V171, P624
[6]   Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch [J].
Hirvonen, E ;
Cacciatore, B ;
Wahlstrom, T ;
Rita, H ;
WilenRosenqvist, G .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1997, 104 :26-31
[7]  
HOLST J, 1993, ACTA OBSTET GYNECOL, V62, P49
[8]   Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women [J].
Hulley, S ;
Grady, D ;
Bush, T ;
Furberg, C ;
Herrington, D ;
Riggs, B ;
Vittinghoff, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (07) :605-613
[9]   Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens [J].
Jick, H ;
Derby, LE ;
Myers, MW ;
Vasilakis, C ;
Newton, KM .
LANCET, 1996, 348 (9033) :981-983
[10]   EFFECTS OF HORMONAL REPLACEMENT ON LIPIDS AND LIPOPROTEINS IN POSTMENOPAUSAL WOMEN [J].
LOBO, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (05) :925-930